Cardiac Pacemaker Device Replacement with MCC DRG Reimbursement

DRG 258 addresses inpatient cardiac pacemaker device replacement cases complicated by a Major Complication or Comorbidity, covering scenarios such as device infection, lead failure with systemic impact, or other severe comorbid conditions. This classification matters for inpatient reimbursement because the Diagnosis-Related Group assignment determines Medicare payment level and reflects increased resource use for more complex clinical presentations.

DRG 258 Overview

DRG 258 covers inpatient admissions for cardiac pacemaker device replacement when a Major Complication or Comorbidity is present, typically involving elderly patients with device malfunction, lead complications, infection, or systemic illness that increases resource use. This Diagnosis-Related Group groups cases with higher clinical complexity and resource intensity, which affects Medicare payment classification and hospital reimbursement. The presence of a Major Complication or Comorbidity shifts cases into this higher-severity category, influencing payment relative to lower-severity pacemaker replacement groups.

Perioperative device management and complication prevention studies: Trials in this area examine protocols and interventions to reduce intraoperative and early postoperative complications during cardiac pacemaker generator replacement in patients with multiple comorbidities and major complications or comorbidity (MCC), such as lead malfunction, device infection, or hemodynamic instability. These studies typically enroll older adults with prior device implants who require replacement and may test optimized antibiotic regimens, standardized extraction versus abandonment strategies for problematic leads, or intraoperative monitoring pathways to reduce acute events. Results are directly relevant to providers and payers because reducing perioperative complications can shorten length of stay, lower readmission risk, and decrease high-cost resource use associated with MCC-coded encounters.
Comparative effectiveness studies of replacement techniques and device configurations: Research comparing different surgical approaches (e.g., pocket revision versus full generator exchange, lead revision versus lead extraction and reimplantation) and device options (including upgrades to dual-chamber or biventricular systems) focuses on clinical outcomes, complication rates, and device performance in patients whose complexity warrants MCC coding. These trials enroll patients who present for replacement with varying lead integrity, infection history, or pacing needs, and measure outcomes such as device-related adverse events, need for reintervention, and functional cardiac measures over medium-term follow-up. The findings help clinicians choose strategies that balance upfront procedural risk against long-term benefit and inform payers about cost-effectiveness and resource allocation for high-risk replacement cases.
Post-discharge outcomes and care-coordination trials: Studies here evaluate transitional care interventions, remote monitoring programs, and structured follow-up pathways for patients discharged after pacemaker replacement with serious comorbidities or complications. They target medically complex populations prone to readmission, device-related infections, or heart-failure exacerbations, assessing metrics like 30- and 90-day readmission rates, emergency department use, patient-reported symptoms, and identification of device dysfunction via remote telemetry. Evidence from these trials is important to providers and payers because effective post-discharge management can reduce costly readmissions, improve device surveillance, and support value-based payment models for patients in this DRG.

Perioperative device management and complication prevention studies: Trials in this area examine protocols and interventions to reduce intraoperative and early postoperative complications during cardiac pacemaker generator replacement in patients with multiple comorbidities and major complications or comorbidity (MCC), such as lead malfunction, device infection, or hemodynamic instability. These studies typically enroll older adults with prior device implants who require replacement and may test optimized antibiotic regimens, standardized extraction versus abandonment strategies for problematic leads, or intraoperative monitoring pathways to reduce acute events. Results are directly relevant to providers and payers because reducing perioperative complications can shorten length of stay, lower readmission risk, and decrease high-cost resource use associated with MCC-coded encounters.
Comparative effectiveness studies of replacement techniques and device configurations: Research comparing different surgical approaches (e.g., pocket revision versus full generator exchange, lead revision versus lead extraction and reimplantation) and device options (including upgrades to dual-chamber or biventricular systems) focuses on clinical outcomes, complication rates, and device performance in patients whose complexity warrants MCC coding. These trials enroll patients who present for replacement with varying lead integrity, infection history, or pacing needs, and measure outcomes such as device-related adverse events, need for reintervention, and functional cardiac measures over medium-term follow-up. The findings help clinicians choose strategies that balance upfront procedural risk against long-term benefit and inform payers about cost-effectiveness and resource allocation for high-risk replacement cases.
Post-discharge outcomes and care-coordination trials: Studies here evaluate transitional care interventions, remote monitoring programs, and structured follow-up pathways for patients discharged after pacemaker replacement with serious comorbidities or complications. They target medically complex populations prone to readmission, device-related infections, or heart-failure exacerbations, assessing metrics like 30- and 90-day readmission rates, emergency department use, patient-reported symptoms, and identification of device dysfunction via remote telemetry. Evidence from these trials is important to providers and payers because effective post-discharge management can reduce costly readmissions, improve device surveillance, and support value-based payment models for patients in this DRG.

OpenPayer

Summary & Overview

Cardiac Pacemaker Device Replacement with MCC: Inpatient Reimbursement Overview

DRG 258 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes